{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:28:05Z","timestamp":1790980085311,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists have emerged as an effective strategy for treatment intensification in type 2 diabetes mellitus (T2DM). However, long-term real-world data on their metabolic, \u03b2-cell, and renal effects remain limited. This study aimed to evaluate the 12-month real-world outcomes of insulin glargine\/lixisenatide (iGlarLixi) therapy. Methods: This retrospective observational study included 78 patients with T2DM who were initiated on iGlarLixi and followed for 12 months. Clinical and laboratory parameters were assessed at baseline, 3 months, and 12 months. Changes in anthropometric, glycemic, biochemical, and renal parameters were analyzed. Early (3-month) changes were evaluated as predictors of long-term outcomes using correlation and receiver operating characteristic (ROC) analyses. Results: Median HbA1c decreased from 9.0% to 8.2% at 12 months (p = 0.015), with clinically meaningful improvement (\u22651% reduction) observed in 21 (26.9%) patients. Body weight decreased significantly from 93.0 kg to 89.5 kg (p &lt; 0.001). C-peptide levels increased from 2.46 to 3.00 ng\/mL (p = 0.016). Median albumin-to-creatinine ratio (ACR) showed statistically significant paired changes; however, group-level median values remained similar over time. A reduction in albuminuria was observed in 34 (54.8%) of patients with available paired data. Exploratory ROC analyses suggested that early changes in body weight (AUC: 0.82), HbA1c (AUC: 0.74), and C-peptide (AUC: 0.76) may be associated with long-term outcomes. A combined model incorporating early weight and C-peptide changes showed improved exploratory predictive performance (AUC: 0.88). Conclusions: In a real-world setting, iGlarLixi therapy was associated with significant improvements in glycemic control and body weight, along with increased C-peptide levels that may reflect improved endogenous insulin secretion. While group-level renal changes were modest, individual-level improvements in albuminuria were observed in a substantial proportion of patients. Early treatment responses may serve as practical predictors of long-term outcomes, supporting a personalized approach to diabetes management. These findings should be interpreted in the context of concomitant therapies and comorbidities that may have influenced metabolic and renal outcomes in routine clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15135049","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"5049","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine\/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2992-1511","authenticated-orcid":false,"given":"Sadettin","family":"Ozturk","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gaziantep City Hospital, 27100 Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Melis Balo\u011flu","family":"Akyol","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gaziantep City Hospital, 27100 Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"M\u0142ynarska, E., Czarnik, W., Dzie\u017ca, N., J\u0119draszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., and Franczyk, B. (2025). Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031094"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc26-S004","article-title":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14656566.2025.2504702","article-title":"The contemporary landscape of cardiovascular optimization in type 2 diabetes: Overcoming barriers to evidence-based use of newer antihyperglycemic agents","volume":"26","author":"Malas","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cassataro, G., Geraci, G., Giusti, M.A., Maida, C., Maggio, V., Rizzo, M., and Mattina, A. (2026). The Cardiovascular Burden of Diabetes: Risk Factors, Clinical Phenotypes, and Personalized Cardiometabolic Management. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062358"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Caturano, A., Galiero, R., Rocco, M., Tagliaferri, G., Piacevole, A., Nilo, D., Di Lorenzo, G., Sardu, C., Vetrano, E., and Monda, M. (2024). Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092039"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tiwari, D., Loh, W.J., and Aw, T.C. (2026). Paradigm Shifts in Diabetes Management: Key Highlights from the 2026 American Diabetes Association Standards of Care in Diabetes. LabMed, 3.","DOI":"10.3390\/labmed3020010"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13300-025-01838-0","article-title":"Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting\u2014Expert Group Recommendations from Kuwait","volume":"17","author":"Aldahi","year":"2026","journal-title":"Diabetes Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/dom.12961","article-title":"Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine\/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial","volume":"19","author":"Wysham","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s13300-024-01644-0","article-title":"Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U\/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI","volume":"15","author":"Kis","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1111\/dom.15609","article-title":"Real-life effectiveness of iGlarLixi (insulin glargine 100\u2009U\/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use","volume":"26","author":"Seufert","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/dom.15027","article-title":"iGlarLixi (insulin glargine 100 U\/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data","volume":"25","author":"Guja","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s13300-021-01128-5","article-title":"Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U\/mL and Lixisenatide, in People with Type 2 Diabetes","volume":"12","author":"Kis","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108478","DOI":"10.1016\/j.diabres.2020.108478","article-title":"Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus","volume":"170","author":"Giorgino","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/dom.16161","article-title":"Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial","volume":"27","author":"Seufert","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s12325-025-03135-5","article-title":"Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study","volume":"42","author":"Kaneto","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1111\/dom.16591","article-title":"Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study","volume":"27","author":"Malik","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12020-025-04207-w","article-title":"Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"88","author":"Li","year":"2025","journal-title":"Endocrine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12020-024-03868-3","article-title":"iGlarLixi for type 2 diabetes: A systematic review and meta-analysis","volume":"86","author":"Liu","year":"2024","journal-title":"Endocrine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e060852","DOI":"10.1136\/bmjopen-2022-060852","article-title":"Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: A prospective cohort study (STAR.Ro)","volume":"12","author":"Bala","year":"2022","journal-title":"BMJ Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13300-022-01328-7","article-title":"Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study","volume":"14","author":"Candido","year":"2022","journal-title":"Diabetes Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.endmts.2024.100164","article-title":"Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)","volume":"15","author":"Jammah","year":"2024","journal-title":"Endocr. Metab. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11886-026-02356-6","article-title":"GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes","volume":"28","author":"Ramadurgum","year":"2026","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101282","DOI":"10.1016\/j.xkme.2026.101282","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives","volume":"8","author":"Meier","year":"2026","journal-title":"Kidney Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rroji, M., and Spasovski, G. (2024). Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030657"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.kint.2025.10.005","article-title":"REMODELing mechanistic trials for kidney disease: A multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide","volume":"109","author":"Pruijm","year":"2026","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., and De Cosmo, S. (2019). GLP-1 Receptor Agonists and Kidney Protection. Medicina, 55.","DOI":"10.3390\/medicina55060233"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41581-026-01066-0","article-title":"Insulin resistance and hyperinsulinaemia in kidney disease: Mechanisms and metabolic effects","volume":"22","author":"Zaitoon","year":"2026","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.12986","article-title":"Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment","volume":"19","author":"Hanefeld","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1111\/dom.70481","article-title":"Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial","volume":"28","author":"Fountoulakis","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","article-title":"Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus","volume":"316","author":"Tonneijck","year":"2019","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00592-020-01634-1","article-title":"The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: A cross-sectional study","volume":"58","author":"Dario","year":"2020","journal-title":"Acta Diabetol."},{"key":"ref_36","first-page":"349","article-title":"An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus","volume":"21","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4093\/dmj.2026.0034","article-title":"Redefining \u03b2-Cell Function in Type 2 Diabetes Mellitus: From Comprehensive Assessment to Precision Medicine","volume":"50","author":"Kim","year":"2026","journal-title":"Diabetes Metab. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13619-025-00255-9","article-title":"Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets","volume":"14","author":"Parsi","year":"2025","journal-title":"Cell Regen."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/dom.14036","article-title":"Efficacy and safety of insulin glargine\/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial","volume":"22","author":"Terauchi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s12325-020-01614-5","article-title":"Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes","volume":"38","author":"Skolnik","year":"2021","journal-title":"Adv. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5049\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:34:49Z","timestamp":1782783289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":40,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135049"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135049","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}